Originally Posted by bigwalleye1
Not trying to argue, but looks like there's a discrepancy. The farm bill talks about .3% or less, while the article you cite says .1 or less is legal as a schedule V.
This thing needs a clear statement from the DEA. Anybody see anything from them definitively? I see lots of CBD sites offering their interpretations, but that's somewhat self serving.
The 0.03% threshold strikes a chord. I previously mentioned my CBD supply is backed by 3rd party independent chemical analysis finding 0.00% THC. The label on my source says:” Less than .03% THC content”. Obviously that label statement establishes a legal threshold.
In a broader context, the remaining confusion about CBD is aggravated because of the lack of FDA analysis, conclusions, and regulation. How can law enforcement make a clear cut statement when FDA approvals don’t exist?
This contradiction hasn’t been missed by our lawmakers. Only several weeks ago, Sen McConnell attached the following language to some funding legislation:
“As previously mentioned, the Committee provides $2,000,000 for research, policy evaluation, market surveillance, issuance of an enforcement discretion policy, and appropriate regulatory activities with respect to products under the jurisdiction of the Food and Drug Administration which contain cannabidiol (CBD) and meet the definition of hemp, as set forth in section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o). Within 90 days, FDA shall provide the Committee with a report regarding the Agency’s progress toward obtaining and analyzing data to help determine a policy of enforcement discretion, and the process in which CBD meeting the definition of hemp will be evaluated for use in products. Within 120 days, FDA shall issue a policy of enforcement discretion with regard to certain products containing CBD meeting the definition of hemp as defined by section 297A of the Agricultural Marketing Act of 1964 (7 U.S.C. 1639). Such enforcement discretion shall be in effect until FDA establishes a process for stakeholders to notify FDA for use of CBD in products that include safety studies for intended use per product, and makes a determination about such product. FDA is encouraged to consider existing and ongoing medical research related to CBD that is being undertaken pursuant to an Investigation New Drug (IND) application in the development of a regulatory pathway for CBD in products under the jurisdiction of FDA and to ensure that any future regulatory activity does not discourage the development of new drugs.”